<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01506791</url>
  </required_header>
  <id_info>
    <org_study_id>50631</org_study_id>
    <nct_id>NCT01506791</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Desloratadine and Pseudoephedrine Extended-release Tablets Under Fed Conditions</brief_title>
  <official_title>Randomized, Open-Label, 2-Way Crossover, Bioequivalence Study of Desloratadine and Pseudoephedrine 5 mg/240 mg Extended-Release Tablet and Clarinex-D® 24-Hour (Reference) Following a 5 mg/240 mg Dose in Healthy Subjects Under Fed Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label, randomised, 2-way crossover, comparative bioequivalence study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study was to compare the rate and extent of absorption of Dr. Reddy's&#xD;
      Laboratories Ltd., India, desloratadine-pseudoephedrine and Schering Corporation,&#xD;
      U.S.A.(Clarinex-D® 24-HOUR), desloratadine-pseudoephedrine, administered as a 1 x 5 mg/240 mg&#xD;
      extended-release tablet under fed conditions. The treatment phases were separated by a&#xD;
      washout period of 14 days. 44 subjects were dosed and were enrolled in the study; 43 of these&#xD;
      enrolled subjects completed the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">April 2006</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under curve(AUC)</measure>
    <time_frame>Pre-dose 0.5,1,1.5,2,2.5,3,3.5,4,4.5,5,6,7,8,9,10,12,24,36,48,72,96,120 and 144 hours post-dose</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Desloratadine and pseudoephedrine ER tablets 5/240 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Desloratadine and pseudoephedrine ER tablets 5/240 mg of Dr. Reddy's Laboratories Limited</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clarinex D 24-hour</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clarinex D-24 of Schering Corporation Inc USA</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Desloratadine and pseudoephedrine</intervention_name>
    <description>Desloratadine and pseudoephedrine 5/240 mg</description>
    <arm_group_label>Clarinex D 24-hour</arm_group_label>
    <arm_group_label>Desloratadine and pseudoephedrine ER tablets 5/240 mg</arm_group_label>
    <other_name>Clarinex D-24</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Is the individual a healthy, normal adult man or woman who volunteers to participate?&#xD;
&#xD;
          -  Is s/he within 18 to 45 years of age, inclusive?&#xD;
&#xD;
          -  Is his/her BMI between 19 and 30 inclusive?&#xD;
&#xD;
          -  Is she willing to avoid pregnancy by abstaining from sexual intercourse with a&#xD;
             non-sterile male partner, or by the use one of the following methods: diaphragm +&#xD;
             spermicide or condom + spermicide (at least 14 days before dosing), intra-uterine&#xD;
             contraceptive device or hormonal contraceptives (at least 4 week prior to dosing) or&#xD;
             has she been surgically sterile or post-menopausal at least six months prior to&#xD;
             entering into the study?&#xD;
&#xD;
          -  Is s/he considered reliable and capable of understanding his/her responsibility and&#xD;
             role in the study?&#xD;
&#xD;
          -  Has s/he provided written informed consent?&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Does the individual have a history or allergy or hypersensitivity to desloratadine or&#xD;
             pseudoephedrine, milk or eggs?&#xD;
&#xD;
          -  Does s/he have clinically significant laboratory abnormalities that would interfere&#xD;
             with the conduct or interpretation of the study or jeopardize his/her safety?&#xD;
&#xD;
          -  Does s/he have significant history or clinical evidence of auto-immune,&#xD;
             cardiovascular, gastrointestinal, hematological, hematopoietic, hepatic, neurological,&#xD;
             ongoing infection, pancreatic, or renal disease that would interfere with the conduct&#xD;
             or interpretation of the study or jeopardize his/her safety?&#xD;
&#xD;
          -  Is she nursing?&#xD;
&#xD;
          -  Does s/he have serious psychological illness?&#xD;
&#xD;
          -  Does s/he have significant history (within the past year) or clinical evidence of&#xD;
             alcohol or drug abuse?&#xD;
&#xD;
          -  Does s/he have a positive urine drug screen or a positive HIV-I, or hepatitis B or C&#xD;
             screen, or a positive pregnancy test?&#xD;
&#xD;
          -  Is s/he unable to refrain from the use of alcohol or xanthine-containing foods or&#xD;
             beverages during periods beginning 48 hours prior to study drug administration and&#xD;
             ending when the last blood sample has been taken in each study period?&#xD;
&#xD;
          -  Has s/he used any prescription drug, other than hormonal contraceptives, during the 14&#xD;
             day period prior to study initiation, or any OTC drug during the 72 hour period&#xD;
             preceding study initiation?&#xD;
&#xD;
          -  Is s/he unable to refrain from the use of all concomitant medications, other than&#xD;
             hormonal contraceptives, during the study?&#xD;
&#xD;
          -  Has s/he donated or lost blood or participated in a clinical study which involved the&#xD;
             withdrawal of a large volume of blood (480 mL or more), during the six week period&#xD;
             preceding study initiation?&#xD;
&#xD;
          -  Has s/he donated plasma during the two week period preceding study initiation?&#xD;
&#xD;
          -  Has s/he received an investigational drug during the 30 day period preceding study&#xD;
             initiated?&#xD;
&#xD;
          -  Has s/he used any tobacco products in the 3 months preceding drug administration?&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio R Pizarro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>SFBC Anapharm</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SFBC Ft Myers Inc</name>
      <address>
        <city>Broadway</city>
        <state>Florida</state>
        <zip>33901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2006</verification_date>
  <study_first_submitted>September 27, 2011</study_first_submitted>
  <study_first_submitted_qc>January 5, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 10, 2012</study_first_posted>
  <last_update_submitted>January 5, 2012</last_update_submitted>
  <last_update_submitted_qc>January 5, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bioequivalence</keyword>
  <keyword>Desloratadine and pseudoephedrine</keyword>
  <keyword>crossover</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malnutrition</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pseudoephedrine</mesh_term>
    <mesh_term>Ephedrine</mesh_term>
    <mesh_term>Desloratadine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

